Galmed Pharmaceuticals (GLMD) Free Cash Flow (2013 - 2025)

Galmed Pharmaceuticals' Free Cash Flow history runs 13 years deep, the most recent figure standing at -$1.9 million for Q4 2025.

• In Q4 2025, Free Cash Flow fell 1.94% year-over-year to -$1.9 million; the TTM figure through Dec 2025 stood at -$6.3 million (down 7.4% YoY), while the FY2025 annual figure was -$6.3 million, down 7.4% from the prior year.
• Free Cash Flow was -$1.9 million for Q4 2025 at Galmed Pharmaceuticals, down from -$1.9 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$255000.0 in Q1 2022 to a low of -$11.1 million in Q2 2022.
• Historically, Free Cash Flow has averaged -$3.5 million across 5 years, with a median of -$1.9 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Free Cash Flow jumped 97.25% in 2022, then tumbled 563.14% in 2023.
• A 5-year view of Free Cash Flow shows it stood at -$7.0 million in 2021, then surged by 42.5% to -$4.0 million in 2022, then jumped by 77.72% to -$898000.0 in 2023, then sank by 112.47% to -$1.9 million in 2024, then fell by 1.94% to -$1.9 million in 2025.
• The last three Free Cash Flow figures came in at -$1.9 million (Q4 2025), -$1.9 million (Q3 2025), and -$1.3 million (Q2 2025), per Business Quant data.